

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND COMPLIANCE WITH RULES 5.05(1), 5.06, 5.28, 5.33
AND 5.36A OF THE GEM LISTING RULES**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) is pleased to announce that Mr. HEUNG Pik Lun (“**Mr. HEUNG**”) has been appointed as an independent non-executive Director of the Company and a member of the audit committee and the nomination committee of the Company with effect from 15 September 2023.

Mr. HEUNG Pik Lun, aged 61, is a senior executive with extensive experience in administrative management. With over 20 years of business experience in both China and Hong Kong, Mr. HEUNG has a wealth of experience in market development. He has also managed several listed companies in China and Hong Kong, demonstrating a deep understanding and proficient skills in corporate management and capital market. He holds a Royal Chartered Surveyor qualification.

Mr. HEUNG has not entered into any service contract for his duties as the independent non-executive Director with the Company. He will be entitled to receive an annual director’s fee of HK\$60,000 which was determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company’s performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. HEUNG (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on GEM (“**GEM**”) of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”)) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to the appointment of Mr. HEUNG is needed to be brought to the attention of the shareholders of the Company.

Mr. HEUNG has confirmed that he meets the independence criteria as set out in Rule 5.09 of the GEM Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. HEUNG for joining the Company.

COMPLIANCE WITH RULES 5.05(1), 5.06, 5.28, 5.33 AND 5.36A OF THE GEM LISTING RULES

As disclosed in the announcement of the Company dated 15 August 2023, an application has been made by the Company to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for, and the Stock Exchange has granted, a waiver from strict compliance with Rules 5.05(1), 5.06, 5.28, 5.33 and 5.36A of the GEM Listing Rules and an extension of time for a period of one month from 15 August 2023 to 15 September 2023 for filling the vacancies. Following the appointment of Mr. HEUNG with effect from 15 September 2023, the Company has complied with the Rules 5.05(1), 5.06, 5.28, 5.33 and 5.36A of the GEM Listing Rules.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 15 September 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at <https://www.hkgem.com> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.